title: [Prevalence of mutations responsible for resistance to antiretroviral preparations among HIV-1 variants circulating in Novosibirsk region].
abstract: OBJECTIVE
  Analyze the diversity and prevalence of mutations in human immunodeficiency virus type 1 (HIV-1) genome emerging in response to antiretroviral therapy isolated from HIV-infected individuals of Novosibirsk region in 2010, 2011.
  
  
  METHODS
  Detection of mutations in HIV-1 genome responsible for the resistance to. antiretroviral preparations (ARVP) was carried out by determination of pol gene nucleotide sequence and subsequent analysis ofthe data obtained by program HIVdb: Genotypic Resistance Interpretation Algorithm.
  
  
  RESULTS
  HIV-1 resistance mutations to antiretroviral preparations were detected in 23.6% of the total number of the studied samples. The most prevalent mutations are those conditioning resistance to nucleoside and non-nucleoside reverse transcriptase inhibitors (M184V, Y181C and K103N). In studies of HIV-1 isolated from 4 patients who had not received antiretroviral therapy (ARVT) transmission of HIV-1 resistant to various groups of preparations was detected.
  
  
  CONCLUSIONS
  The detected facts of ARVP resistant HIV-1 circulation among patients who had not received ARVT and the data obtained on the mutations emerging in response to therapy underline the relevance of administration of HIV-1 resistance profile study during both decrease of ARVT effectiveness and primary administration of therapy to HIV infected patients.
authors.forename: N M
authors.initials: NM
authors.lastname: Gashnikova
authors.forename: V V
authors.initials: VV
authors.lastname: Bogachev
authors.forename: P B
authors.initials: PB
authors.lastname: Baryshev
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Meshcheriakova
authors.forename: E N
authors.initials: EN
authors.lastname: Savochkina
authors.forename: N Ia
authors.initials: NIa
authors.lastname: Chernousova
mesh_terms: D000328:Adult; D000465:Algorithms; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D015751:Genes, pol; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D006801:Humans; D058889:Molecular Typing; D009154:Mutation; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology*; D017422:Sequence Analysis, DNA; D012800:Siberia / Q000453:epidemiology; D014779:Virus Replication / Q000187:drug effects
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D054303:HIV Reverse Transcriptase